Is giritinib fumarate tablets covered by medical insurance?

Giritinib fumarate tablets, as a new generation, highly specific FLT3 inhibitor, have been successfully launched in China. This drug is a very important treatment option for patients with FLT3 mutated acute myeloid leukemia (AML). However, despite its remarkable efficacy, it is not currently covered by medical insurance in China, which undoubtedly increases the financial burden on patients.

Giritinib is a highly specificFLT3 inhibitor. Compared with traditional FLT3 inhibitors, giritinib has higher selectivity and inhibitory activity, and has a significant effect on FLT3 mutated AML patients. After the drug was first approved in Japan, it was quickly launched in many countries and regions around the world, including China, bringing new treatment hope to many patients.

Giritinib fumarate tablets provide a new treatment option for FLT3 mutated AML patients. The launch of this drug is undoubtedly a major progress in the domestic medical field. But so far, it has not been included in medical insurance coverage. This means that patients need to pay the full amount out of pocket when purchasing this drug, which undoubtedly puts considerable financial pressure on patients.

The adjustment of the medical insurance catalog is a complex process that requires comprehensive consideration of the efficacy, safety, economy and other aspects of the drug. At present, giritinib fumarate tablets may not be included in medical insurance due to reasons such as high price and incomplete clinical data.

Giritinib fumarate tablets are a very important therapeutic drug for patients with FLT3mutated AML. However, the lack of medical insurance makes it financially unaffordable for many patients. Therefore, they eagerly hope that this drug can be included in medical insurance as soon as possible to reduce the financial burden.